On Friday, Shares of Wells Fargo & Company (NYSE:WFC), lost -0.40% to $57.94.
Wells Fargo & Company, stated net income of $5.7 billion, or $1.03 per diluted common share, for second quarter 2015, contrast with $5.7 billion, or $1.01 per share, for second quarter 2014, and $5.8 billion, or $1.04 per share, for first quarter 2015.
Loans
Total loans were $888.5 billion at June 30, 2015, up $27.2 billion from March 31, 2015. Growth was broad-based and was led by commercial and industrial, and commercial real estate, which comprised of $11.5 billion from the GE Capital loan purchase and financing transaction declared in the first quarter. Core loan growth was $29.4 billion, as non-planned/liquidating portfolios declined $2.2 billion in the quarter. Total average loans were $870.4 billion in the second quarter, up $7.2 billion from the first quarter.
Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.
Shares of XOMA Corporation (NASDAQ:XOMA), declined -3.21% to $4.52, during its last trading session.
XOMA Corporation, declared the Company will host a conference call on Thursday, August 6, 2015, at 4:30 p.m. Eastern daylight time to talk about second quarter 2015 financial results and provide an update on gevokizumab’s global clinical programs.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçets disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases.
Finally, WestRock Company (NYSE:WRK), ended its last trade with -0.91% loss, and closed at $61.75.
Ingevity will be the new name of MWV Specialty Chemicals division of WestRock Company. It will start transacting business as Ingevity on September 1. As formerly declared, the business is slated to be spun off as an independent, publicly-traded company around the end of the year.
The separation is predictable to be executed by means of a tax-free spinoff of the Specialty Chemicals business to shareholders of WestRock Company, resulting in two independent, publicly traded companies. The spinoff is predictable to be accomplished around the end of the calendar year, subject to customary conditions. There can be no assurance regarding the ultimate timing of the spinoff or that it will be accomplished.
WestRock Company manufactures and sells containerboard and paperboard products in the Unites States, Canada, Mexico, Chile, Argentina, and Puerto Rico. The company operates through four segments: Corrugated Packaging, Consumer Packaging, Merchandising Displays, and Recycling.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
